• J.POD ^® TOULOUSE, FRANCE (EU) BRINGS A DISRUPTIVE, FLEXIBLY SCALABLE ORGANIC MANUFACTURING TECHNOLOGY TO THE REGION
• PRODUCTION FACILITIES EXPECTED TO BE OPERATIONAL IN H2 2024

HAMBURG, GERMANY / ACCESSWIRE / September 16, 2-022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today officially started construction of its J.POD ^® Biologics manufacturing facility at Evotec’s Curie campus in Toulouse, France. J.POD ^® Toulouse, France (EU), the second facility of its kind and the first on European soil, will use Just – Evotec Biologics’ flexible J.POD ^® Technology to provide much-needed clinical and commercial biologics manufacturing capacity.

Biologics are a highly effective therapeutic option with broad applicability for many indications. However, traditional fed-batch manufacturing presents significant challenges, particularly when scaling up from clinical to commercial supply. With a modular continuous manufacturing setup, the J.POD ^® Technology enables high-intensity cGMP manufacturing of biologics in flexibly scalable quantities, significantly reducing both scale-up risks and manufacturing costs.

During a ceremony at the Curie campus, Jean-Luc Moudenc, President of Toulouse Métropole and Mayor of Toulouse, Jalil Benabdillah, Vice-President, Economy, Employment, Innovation and Reindustrialization of the Occitania region, and Étienne Guyot, Prefect of Haute-Garonne and Occitania, joined the management of Evotec and its subsidiary Just – Evotec Biologics to lay the foundation for the new facility. J.POD ^® Toulouse, France (EU), is expected to be operational in the second half of 2024, creating more than 150 new high-skilled jobs at Evotec’s Campus Curie in Toulouse.

Just – Evotec Biologics opened the first facility of its kind, J.POD ^® Redmond, WA (USA), August 2021. The first production runs for valued partners, including the US Department of Defense, have been…